Sustained Remission Over 36 Months of Advanced Hepatocellular Carcinoma After Short-Term Sorafenib Therapy

Excerpt

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related mortality worldwide [1]. Two phase 3, randomized, double-blind, placebo-controlled trials showed that sorafenib improved overall survival of patients with advanced HCC [2, 3]. Despite the survival improvement, radiologic tumor regression was observed in a very small proportion of patients with sorafenib therapy. There are several reports of complete remission of HCC after sorafenib therapy [4‐12]. However, continued regression of HCC after short-term sorafenib therapy has not yet been reported. Therefore, we report a case of advanced HCC which regressed completely in six months after sorafenib therapy for four weeks only. After achieving complete remission, the patient remained in complete remission for up to 36 months. …